Takeda and HUTCHMED Announce New Drug Application (NDA) - Fruquintinib - for Treatment of Experiencing Metastatic Colorectal Cancer Has Been Accepted for Priority Review
Friday, May 26, 2023
OSAKA, Japan, CAMBRIDGE, Mass., HONG KONG, SHANGHAI & FLORHAM PARK, NJ--( BUSINESS WIRE )--Takeda ( TSE:4502/NYSE:TAK ) & HUTCHMED (China) Limited (Nasdaq/AIM:HCM, HKEX :13) ( HUTCHMED ) today announced that the FDA (Food and Drug Administration) has granted permission to conduct a priority review of the new drug application (NDA) for fruquintinib, a Potent, highly selective inhibitor of vascular endothelial growth factor receptor (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (CRC).
The original text of this announcement, written in the source language, is the official version which is authentic. Translations are offered solely for the convenience of the reader and must refer to the text in the original language, which is the only legally valid one.
